Gland Pharma Announces 48th AGM, E-voting, and Final Dividend Details
Gland Pharma's 48th AGM is on August 25, 2026. Remote e-voting is from August 22-24, 2026. A final dividend of ₹20 per share is recommended. The record date for the dividend is August 11, 2026.
The announcement is important for shareholders as it provides crucial dates and procedures for the AGM and dividend distribution, which are key events for investors.
The announcement is a routine disclosure regarding the company's AGM, e-voting, and dividend information. It does not contain any new financial performance data or strategic shifts that would significantly alter the company's outlook.
Gland Pharma Limited has announced the details for its 48th Annual General Meeting (AGM), scheduled to be held on Tuesday, August 25, 2026, at 11:00 a.m. IST through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
The company has provided instructions for e-voting, with remote e-voting commencing on Saturday, August 22, 2026, at 9:00 AM IST and concluding on Monday, August 24, 2026, at 5:00 PM IST. A cut-off date of Tuesday, August 18, 2026, has been set for determining voting eligibility.
Furthermore, the Board of Directors has recommended a Final Dividend of ₹20 per equity share for the Financial Year ended March 31, 2026, subject to shareholder approval at the AGM. If approved, the dividend payment will be made within thirty days of shareholder approval, after deduction of tax at source. The record date for determining eligibility for this dividend is August 11, 2026. Shareholders have been provided with detailed instructions regarding Income Tax compliances, including procedures for claiming non-deduction or lower deduction of TDS, with a deadline of August 16, 2026, for submitting necessary documents.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.